Steven A. Goldstein Collegiate Professor of Biomedical Engineering
Biomedical Engineering, Chemical Engineering
Shea was recruited to Northwestern University’s Department of Chemical and Biological Engineering and was on the faculty from 1999 to 2014. In 2014, Shea was recruited back to the University of Michigan as chair of the Department of Biomedical Engineering, with his recruitment coinciding with the endowment of the chair position by William and Valerie Hall. He is the Steven A. Goldstein Collegiate Professor of Biomedical Engineering and is an internationally recognized researcher at the interface of regenerative medicine, drug and gene delivery, and immune-engineering, whose focus is on preventing tissue degeneration or promoting tissue regeneration. His projects include islet transplantation for diabetes therapies, nerve regeneration for treating paralysis, autoimmune diseases and allogeneic cell transplantation, and diagnostics for immune dysfunction in cancer and autoimmunity.
Shea has published more than 250 manuscripts, and has numerous inventions to his credit. He is the PI for the Coulter Foundation Translational Research Program at the University of Michigan. He served as director of Northwestern’s NIH Biotechnology Training Grant. He has received the Clemson Award from the Society for Biomaterials, and has been named the recipient of their 2021 Technology Innovation and Development Award. Shea is a fellow of the American Institute of Medical and Biological Engineering (AIMBE) and the Biomedical Engineering Society (BMES), a member of the editorial boards for multiple journals such as Molecular Therapy, Biotechnology and Bioengineering, and the Journal of Immunology and Regenerative Medicine.
Autoimmune disease, Cancer, Sensors
Community and Professional Affiliation(s)
American Institute of Medical and Biological Engineering | Biomedical Engineering Society
Basic and Translational cancer research
- Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone
- Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
- Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets